A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Inclusion Criteria:
Exclusion Criteria:
Botucatu, São Paulo 18618-686, Brazil
Santo Andr, São Paulo 09030-010, Brazil
Sao Jose Rio Preto, São Paulo 15090-000, Brazil
Cedex 10, Paris 75010, France
Roma, Emilia-Romagna 00168, Italy
Catania, Sicily 95123, Italy